Femasys Receives World's First Regulatory Approval for Non-Surgical Permanent Birth Control System in Europe
核心洞察
Femasys Inc. achieved CE mark certification for its complete FemBloc (搜索) System, marking the first global regulatory approval for non-surgical permanent female birth control.
The FemBloc (搜索) System uses a proprietary blended polymer delivered through fallopian tubes (搜索) to create permanent sterilization without surgery, anesthesia, or recovery downtime.
Commercial launch will begin in Spain through existing partnerships, with the company continuing FDA pivotal trials for U.S. market approval.
Femasys Inc. has achieved a groundbreaking regulatory milestone with the European approval of its FemBloc (搜索) System, becoming the world's first non-surgical permanent birth control solution to receive regulatory endorsement. The company announced on June 25, 2025, that it received Conformité Européenne (CE) mark certification under European Union Medical Device Regulation (EU MDR 2017/745) for the Class III FemBloc blended polymer component, completing the regulatory approval process that began with the delivery system component approval on March 13, 2025.
The approval follows rigorous evaluation by the European Medicines Agency (搜索) (EMA) and subsequent certification by the Notified Body. The FemBloc (搜索) System can now be marketed across the European Economic Area, encompassing 27 European Union member states and three European Free Trade Association countries.
Revolutionary Non-Surgical Approach
FemBloc (搜索) represents a paradigm shift in permanent contraception, offering the first alternative to centuries-old surgical sterilization methods. The system delivers a proprietary blended polymer into both fallopian tubes (搜索) through a patented in-office delivery system. The polymer safely degrades and forms natural scar tissue to permanently block the tubes, eliminating the need for surgical intervention.
"European approval of the entire FemBloc (搜索) System represents a major milestone for Femasys and the field of women's health," stated Kathy Lee-Sepsick, Femasys' CEO and Founder. "It marks the first global regulatory endorsement of our groundbreaking non-surgical permanent birth control solution, following a rigorous scientific evaluation of the technology."
The procedure eliminates traditional surgical risks including anesthesia complications, infection, and recovery downtime, while offering significantly improved cost-effectiveness and accessibility compared to surgical sterilization.
Clinical Evidence and Safety Profile
Published data from initial clinical trials demonstrated compelling effectiveness and a five-year safety profile with high patient and practitioner satisfaction. The clinical evidence supporting FemBloc (搜索)'s approval was published in the Journal of Gynecology and Reproductive Medicine, providing peer-reviewed validation of the technology's safety and efficacy.
The system includes FemChec (搜索), a companion diagnostic product that enables ultrasound-based confirmation of procedure success, ensuring comprehensive patient care and monitoring.
Commercial Strategy and Market Expansion
Femasys is preparing for commercial launch through strategic distribution partnerships, beginning in Spain through existing partners. The company plans to seek additional country approvals across Europe while maintaining focus on its U.S. regulatory pathway.
"Femasys is preparing to make FemBloc (搜索) commercially available through strategic distribution partnerships in select countries in Europe beginning in Spain through our existing partners and will seek additional country approvals while continuing to enroll participants in our FDA IDE-approved late-stage pivotal trial for U.S. approval," Lee-Sepsick explained.
U.S. Market Development
For U.S. FDA approval, enrollment continues in the FINALE pivotal trial (NCT05977751), representing the late-stage clinical development program required for American market entry. The FDA has granted Investigational Device Exemption (IDE) approval for this pivotal study, indicating regulatory alignment on the development pathway.
Broader Women's Health Portfolio
Beyond FemBloc (搜索), Femasys maintains a comprehensive women's health portfolio including FemaSeed (搜索) Intratubal Insemination for fertility treatment and FemVue (搜索) for fallopian tube assessment. Published clinical trial data show FemaSeed demonstrates over twice the effectiveness of traditional intrauterine insemination (IUI) with comparable safety profiles and high satisfaction rates.
The European approval positions Femasys to address significant unmet needs in women's reproductive health, offering healthcare providers and patients a safer, more accessible alternative to traditional surgical sterilization methods that have remained largely unchanged for centuries.